迈威生物2025年净利预亏9亿元至9.95亿元

Core Viewpoint - Maiwei Biotech (688062) is expected to continue incurring losses in 2025, with a projected net profit attributable to shareholders ranging from -900 million to -995 million yuan compared to the previous year [1] Financial Performance - The company anticipates a significant increase in revenue from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC. [1] - There is a notable growth in drug sales revenue compared to the same period last year [1] Cost and Investment - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company maintains a high level of research and development investment, with multiple innovative drugs in critical trial phases [1]